Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.34 |
| ▸ | PTPRC | P08575 | 1/20 | 0.33 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.32 |
| ▸ | WNT3A | P56704 | 1/20 | 0.32 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.31 |
| ▸ | HTR3B | O95264 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29833385 | 1.00 | CYP2A6 (0.43) | CYP2A6MRGPRX4OPRM1OPRK1PTGER4 | |
| SCHEMBL631289 | 0.85 | CYP2A6 (0.61) | CYP2A6MRGPRX4OPRM1OPRK1PTPRC | |
| SCHEMBL28997921 | 0.83 | CYP2A6 (0.42) | CYP2A6MRGPRX4OPRM1OPRK1PTGER4 | |
| SCHEMBL52117 | 0.77 | SIGMAR1 (0.40) | CYP2A6MRGPRX4OPRM1OPRK1PTGER4 | |
| SCHEMBL9111536 | 0.76 | CYP2A6 (0.40) | CYP2A6MRGPRX4OPRM1OPRK1 | |
| SCHEMBL10230281 | 0.76 | CYP2A6 (0.46) | CYP2A6MRGPRX4OPRM1OPRK1PTGER4 | |
| SCHEMBL154793 | 0.76 | CYP2A6 (0.47) | CYP2A6MRGPRX4OPRM1OPRK1SIGMAR1 | |
| SCHEMBL507426 | 0.76 | CYP2A6 (0.71) | CYP2A6MRGPRX4OPRM1OPRK1TPSAB1 | |
| SCHEMBL7465357 | 0.76 | CYP2A6 (0.46) | CYP2A6MRGPRX4OPRM1OPRK1PTGER4 | |
| SCHEMBL8058490 | 0.76 | CYP2A6 (0.46) | CYP2A6MRGPRX4OPRM1OPRK1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114874201-B | Pan-KRAS inhibitor and preparation and application thereof | 思路迪生物医药(上海)有限公司 | 2023-01-20 | — | — | CN | disclosed |
| CN-114874201-A | Pan-KRAS inhibitor and preparation and application thereof | 思路迪生物医药(上海)有限公司 | 2022-08-09 | — | — | CN | disclosed |
| US-6660764-B2 | Telomerase inhibitors such as trans-3-(benzothien-6-yl)-but-2-enoic acid-N-(2-carboxy-phenyl)-amide; use as antitumor agent | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-12-09 | — | — | US | disclosed |
| US-20020123509-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and the preparation thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-05 | — | — | US | disclosed |
| WO-2002051830-A1 | CARBOXAMIDES FOR USE AS TELOMERASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123509-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and the preparation thereof | ASS1, ADCY1, ADCY3 | CYP2A6 39/4885MRGPRX4 1560/4885OPRM1 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.